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Abstract
Background: The aryl hydrocarbon receptor (AhR) is a transcription factor activated by several environmental pollutants,
such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and involved in carcinogenesis and various physiological processes,
including immune response and endocrine functions. Characterization of kinases-related AhR transduction pathway remains
an important purpose.
Results: We performed a kinome-wide siRNA screen in human mammary MCF-7 cells to identify non redundant protein
kinases implicated in the up-regulation of cytochrome P-450 (CYP) 1A1 activity, an AhR referent target, in response to TCDD
exposure. To this aim, we monitored CYP1A1-related ethoxyresorufin-O-deethylase (EROD) activity and quantified cell
density. This normalization was crucial since it allowed us to focus only on siRNA affecting EROD activity and discard siRNA
affecting cell density. Analyses of the cell density data allowed us to identify several hits already well-characterized as
effectors of the cell cycle and original hits. Collectively, these data fully validated the protocol and the siRNA library. Next, 22
novel candidates were identified as kinases potentially implicated in the up-regulation of CYP1A1 in response to TCDD,
without alteration of cell survival or cell proliferation. The siRNA library screen gave a limited number of hits (approximately
3%). Interestingly, four of them are able to bind calmodulin among which the IP3 kinase A (ITPKA) and pregnancy up-
regulated non-ubiquitously expressed CaM kinase (PNCK, also named CaMKIb). Remarkably, for both proteins, their kinase
activity depends on the calmodulin binding. Involvement of ITPKA and PNCK in TCDD-mediated CYP1A1 up-regulation was
further validated by screening-independent expression knock-down. PNCK was finally shown to regulate activation of
CaMKIa, a CaMKI isoform previously reported to interplay with the AhR pathway.
Conclusions: These data fully support a role for both IP3-related kinase and CaMK isoforms in the AhR signaling cascade.
More generally, this study also highlights the interest of large scale loss-of-function screens for characterizing the molecular
mechanism of action of environmental contaminants.
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Introduction
Halogenated aromatic hydrocarbons (AH) such as TCDD
(2,3,7,8-tetrachlorodibenzo-p-dioxin) represent a major class of
environmentally relevant toxicants. In mice and rats, TCDD
exposure leads to a broad spectrum of adverse effects including the
development of cancers and the impairment of endocrine
functions and immunity. TCDD similarly exerts various major
deleterious effects towards human health [1,2,3]. Using aryl
hydrocarbon receptor (AhR) 2/2 mice, the pleiotropic toxicity of
TCDD has been mainly linked to AhR, a basic-helix-loop-helix
(bHLH) transcription factor activated after binding to cognate
ligands exemplified by TCDD [4]. AhR also has important
physiological roles, although the endogenous ligand(s) mediating
these functions is/are as yet unidentified. For example, in AhR2/2
mice, vascular differentiation is severely disrupted, reproductive
ability is impaired, and liver and immune abnormalities are
observed [5].
After TCDD binding, AhR moves to the nucleus, dissociates
from the chaperone complex, and forms a heterodimer with the
AhR nuclear translocator [1]. This heterodimer binds to specific
xenobiotic responsive elements found in the promoter of target
genes and subsequently regulates their transcription [6]. In this way,
TCDD and other AhR agonists markedly induce expression of the
drug-metabolizing enzyme cytochrome P-450 (CYP) CYP1A1,
which is commonly considered as a paradigm of AhR gene targets
and known to detoxify and to bioactivate carcinogens [1]. AH
toxicity appears to be fundamentally a consequence of dysregulation
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of gene expression mediated by AhR [4,7]. Therefore the complete
elucidation of AhR signaling remains an important issue.
In response to xenobiotic exposure, including TCDD and other
AhR agonists, a large number of signaling pathways seems to be
modulated, especially second messengers [8,9] and protein kinases
[10,11]. However, the involvement of their modulation in regulation
of target genes by xenobiotics, including that of CYP1A1 in response
to TCDD, remains relatively poorly documented. These studies are
recurrently based on chemical inhibition of these signaling mediators
[10], although chemical inhibitors are rarely specific of only one
family of kinases [12,13]. Moreover, we and others have
demonstrated that caution may be required when using chemical
inhibitors to study AhR signaling since many of them are agonist/
antagonist of AhR and/or inhibitor of CYP1A1 activity [14,15,16].
Ideally, a combination of chemical and genetic (knock-down or
knock-out) inhibitions should be used to demonstrate the role of a
candidate. To our knowledge, rare candidates have been identified
via this double approach. Among them, members of the calmodulin-
dependent protein kinase (CaMK) family are particularly interesting
[17,18,19]. CaMKs correspond to structurally-related serine/
threonine protein kinases that play important roles in proliferation
[20] and differentiation [21]. We previously reported that activity of
CaMKIa, one of the CaMK isoforms, is most likely required for
TCDD-triggered nuclear translocation of AhR and subsequent up-
regulation of AhR target genes, especially of CYP1A1 [19]. Such
data therefore highlight the Ca2+/CaM/CaMKIa pathway as an
important contributing factor to AhR function. It has also been
hypothesized that other kinases, including c-src [22], CDK4 [23]
and MAPKs [24], may be involved in the AhR signaling pathway.
In order to better and more extensively characterize the
implication of kinases in the AhR cascade, we have analyzed the
consequences of kinase expression knock-down on TCDD-
mediated up-regulation of CYP1A1 activity, using a siRNA
library covering the human kinome. This led us to identify 22
novel candidates as kinases potentially implicated in the up-
regulation of CYP1A1 in response to TCDD, without alteration of
cell survival or cell proliferation.
Results
A kinome RNAi-based screen allows excluding protein
kinases implicated in MCF-7 cell survival and proliferation
To identify nonredundant determinants of the up-regulation of
CYP1A1-related ethoxyresorufin O-deethylase (EROD) activity in
response to TCDD exposure, we designed a robust siRNA screen
targeting 712 kinases of the human kinome. SiRNA were
rehydrated and reverse transfected into the ERa-positive breast
cancer cell line MCF-7 using Dharmafect I (Fig. 1). After 3 days,
cells were exposed to 5 nM TCDD for 6 h, which usually allowed
a strong induction of CYP1A1 transcription and consecutive
EROD activity [19]. EROD activity was measured in kinetic in
the presence of the CYP1A1 substrate ethoxyresorufin. To identify
siRNA affecting cell proliferation and/or cell survival, cell density
was evaluated using Methylene blue dye after the analysis of
EROD activity. This normalization was crucial in our screen since
it allowed us to focus only on siRNA affecting EROD activity
determination and discard siRNA affecting cell density. The two
sets of data (EROD activity and Methylene blue assays) were
collected and analyzed using the R package cellHTS2 especially
developed for cell-based high-throughput RNAi screens [25]. The
methylene blue values and EROD activity values have been
represented in the same plot (in x and y axis, respectively), for the
negative controls (Fig. 2A) and all siRNA (Fig. 2B). These plots
allowed us to visualize the global distribution of all siRNA in a
same plot (Fig. 2B) and to quickly distinguish the proportion of hits.
Negative controls are constituted of non-targeting siRNA (NT1)-
transfected cells and Dharmafect1-exposed cells (without transfec-
tion of siRNA, (Fig. 1)). Positive controls correspond to MCF-7 cells
transfected with siRNA targeting AhR, which abolished EROD
activity without affecting cell density, demonstrating the efficiency of
our protocol (Fig. 2B and Fig. S1). A majority of siRNA did not
display any effect (Fig. 2B), as found in numerous RNAi screens
[26]. A large part of siRNA affected cell survival and/or cell
proliferation leading to a logical reduction of EROD activity. For
the three experiments, results were quite similar (correlation factors:
experiment 1 versus experiment 2: 0.79, experiment 2 versus
experiment 3: 0.81 and experiment 1 versus experiment 3: 0.78, Fig.
S1). It is noteworthy that each siRNA was looked at as independent
of the two other siRNA targeting the same kinase, knowing that
three independent screens were performed.
To further evaluate the quality of the screen and the siRNA
library, a cellHTS2 analysis has been performed based onMethylene
blue data (Fig. S2, Tables S1 and S2). These data have been next
annotated (http://kinase.com/human/kinome/) [27], allowing the
identification of 3 overrepresented kinase families (Tec, Aur and
BRD) (Fig. S2C). Among these candidates, several are already known
to be implicated in cell proliferation and carcinogenesis, such as
Aurora kinase B and ALK [28,29]. Interestingly, various kinases
identified as regulator of cell proliferation and/or viability of MCF-7
cells can be targeted by chemical inhibitors (Fig. S2D). For example,
BTK and ITK, that belong to the same Tec family, may be targeted
by the LFM-A13 inhibitor [30], whereas the multikinase inhibitor
AT9283 [31], a small-molecule inhibitor of kinases with potential
antineoplastic activity and currently in phase II clinical trial, is able to
block kinase activity of Aurora kinase B and JAK2. Altogether, these
data highlighted the robustness of our RNAi-based screen approach
based on loss-of-cell functions.
RNAi-based screen identifies putative protein kinases
regulating TCDD-induced EROD (CYP1A) activity in
mammary MCF-7 cells
To identify kinases regulating TCDD-induced EROD activity,
we performed a second cellHTS2 analysis using the preprocessing
work-flow for two-channel screens (EROD and methylene blue
data) (Fig. S3). At the end of this analysis, the module cellHTS2
displayed two complementary plots to observe hit distribution on
quantile-quantile plot (Fig. 3A), and boxplots of z-scores (Fig. 3B)
for the different types of probes (sample, Pos or Neg). The latest
plot is a screen-wide image plot (Fig. 3C) to visualize the position
of hits in plates (here, the picture corresponds to z-scores
calculated from 3 experiments for individual siRNA). As illustrated
in Fig. 3A, we selected the 150 siRNA causing the most significant
reduction of EROD activity without affecting cell density. Next,
we considered a kinase as a potential hit when at least 2 out of 3
siRNA were found into these 150 z-scores, since it is generally
considered that observation of a phenotype caused by two distinct
siRNA sequences indicates that it is unlikely to be the result of an
off-target effect [32]. This led us to identify 22 kinases (Table 1) as
candidates potentially implicated in up-regulation of EROD
activity in response to TCDD, without affecting cell survival and
proliferation. By contrast, with our criteria (at least 2 out of 3
siRNA), we did not identified kinases which negatively regulate the
AhR pathway (that is, siRNA gene knock-down that would
increase EROD activity). The siRNA library screen gave therefore
a limited number of hits (approximately 3%) interfering with up-
regulation of CYP1 activity.
Gene ontology analysis was performed to characterize these hits
(Table 2). Ten are classified as protein serine/threonine kinases
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and two as protein tyrosine kinases. Interestingly, four of them are
able to bind calmodulin (PNCK, ITPKA, MYO3A and SPHK1).
For ITPKA (IP3 kinase A) and PNCK (pregnancy up-regulated
non-ubiquitously expressed CaM kinase), the kinase activity is
dependent on the calmodulin binding. In addition, two hits are
able to convert IP3 to IP4 (ITPKA and IPMK). The other hits
(Table 1) correspond to poorly characterized kinases (i.e. Lemur
tyrosine kinase 2 and 3) or non-redundant kinases AK3, PMVK,
COASY, SPHK1, MYO3A. A meta-analysis was performed to
integrate this list with gene expression data and protein-protein
interaction data but no convincing associations were found (data
not shown).
Silencing of ITPKA and PNCK decreases TCDD-induced
EROD activity
Among the 22 kinases, we focused our attention on ITPKA and
PNCK since they exhibited a significant impact on EROD activity
whatever the siRNA sequences tested (i.e., 3 out of 3).
Figure 1. Kinome-scale siRNA screen. Flow diagram of the strategy used to identify kinases interfering with MCF-7 cell density and up-regulation
of CYP1A1 activity in human TCDD-exposed cells. Negative controls (siNeg) are non-targeting siRNA (NT1)-transfected cells and Dharmafect1-exposed
cells (without siRNA) (wells A12, B12 and G12, H12). Two positive controls are constituted of cells transfected with siRNA targeting AhR (siPos, G1, H1).
doi:10.1371/journal.pone.0018261.g001
Figure 2. Validation of screen protocol. A, Scatter plot showing the global distribution of control siRNA in function of EROD activity and
methylene blue data. Three experiments were shown in the same plot. For each plate, individual values of negative controls were expressed in
percentage in function of the mean value of the four controls, which was set at 100%. B, Visualization of global distribution of all siRNA of the screen
as explained for A. Negative controls: wells A12, B12 and G12, H12.
doi:10.1371/journal.pone.0018261.g002
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Figure 3. Putative kinases affecting TCDD-induced EROD (CYP1A) activity. A, Hit distribution on quantile-quantile plot and B, boxplots of
z-scores for the different types of probes (sample, Pos or Neg). C, a screen-wide image plot to visualize the position in plates of hits. Here, the picture
corresponds to z-scores calculated from 3 experiments for individual siRNA. One experiment corresponds to 30 plates. Pos for siRNA targeting AhR,
Neg for negative controls constituted of non-targeting siRNA (NT1)-transfected cells and Dharmafect1-exposed cells (without siRNA) and Sample for
36712 siRNA targeting mRNA of human kinases. Hits corresponded to the top 150 z-scores.
doi:10.1371/journal.pone.0018261.g003
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Interestingly, we and others have already shown that calcium,
calmodulin, IP3 [33,34], and members of the CaMKs family
[9,17–19] actively participate to the AhR/CYP1A1 cascade.
Using two siRNA out of 3 available in our library, we
confirmed that knock-down of ITPKA and PNCK expression
reduced CYP1A activity in TCDD-treated MCF-7 cells. In
addition, to compare the effects of ITPKA and PNCK knock-
down on EROD activity to our previous published data with
CaMKIa [13,16,19], we also used 2 other well-characterized
siRNA sequence targeting this kinase [16,19] (siCaMKIa-1 and
a-2, respectively, Fig. 4A). Knock-down consequences were
compared to the same controls (siNT1 and siAhR) as those used
in the screen.
The knock-down of PNCK or ITPKA significantly reduced
TCDD-mediated EROD activity, thus fully validating the results
of the screen (Fig. 4A). SiCaMKIa-transfected cells exposed to
TCDD also displayed lower EROD activity than their TCDD-
treated counterparts transfected with control siNT1, in agreement
Table 1. List of 22 kinases potentially implicated in the up-regulation of EROD activity in response to TCDD.
Symbol z score (mean) Description
ITPKA* 0.97 Inositol 1,4,5-trisphosphate 3-kinase A
PMVK* 1.26 Phosphomevalonate kinase
PNCK* 1.04 Pregnancy upregulated non-ubiquitously expressed CaM kinase
AK3 1.43 Adenylate kinase 3
BMPR2 1.49 Bone morphogenetic protein receptor, type II
CCT2 1.12 Chaperonin containing TCP1, subunit 2 (beta)
COASY 1.29 Coenzyme A synthase (COASY)
HIPK1 1.12 Homeodomain interacting protein kinase 1
IPMK 1.16 Inositol polyphosphate multikinase
LMTK2 1.08 Lemur tyrosine kinase 2
LMTK3 1.08 Lemur tyrosine kinase 3
MPP6 1.17 MAGUK p55 subfamily member 6
MYO3A 1.01 Myosin IIIA
NRK 1.12 Nik related kinase
PIK3C2G 1.00 Phosphoinositide-3-kinase, class 2, gamma polypeptide
PIM2 1.18 Pim-2 oncogene
PRPF4B 1.22 PRP4 pre-mRNA processing factor 4 homolog B (yeast)
SBK1 1.06 SH3-binding domain kinase 1
SNF1LK2 0.86 SNF1-like kinase 2
SPHK1 1.09 Sphingosine kinase 1
TRIB2 1.02 Tribbles homolog 2 (Drosophila)
UCK1 1.25 Uridine-cytidine kinase 1
The mean z-scores were calculated from three individual z-scores (3 siRNA). A kinase was considered as a potential hit when 2/3 or 3/3(*) siRNA were found into the 150
top z-scores using cellHTS2 package.
doi:10.1371/journal.pone.0018261.t001
Table 2. Gene ontology of the 22 kinases potentially implicated in the up-regulation of EROD activity in response to TCDD.
GO GO Coverage Kinase P-value
calmodulin binding 4/140 = 2% SPHK1;PNCK;ITPKA;MYO3A 5.14E205
calmodulin-dependent protein kinase activity 2/14 = 14% PNCK;ITPKA 4.16E204
inositol trisphosphate 3-kinase activity 2/7 = 28% IPMK;ITPKA 1.08E204
uridine kinase activity 1/4 = 25% UCK1 9.30E203
nucleoside triphosphate adenylate kinase activity 1/1 = 100% AK3 3.26E203
phosphomevalonate kinase activity 1/1 = 100% PMVK 3.26E203
pantetheine-phosphate adenylyltransferase activity 1/1 = 100% COASY 3.26E203
D-erythro-sphingosine kinase activity 1/1 = 100% SPHK1 3.26E203
plus-end directed microfilament motor activity 1/1 = 100% MYO3A 3.26E203
Annotation has been performed from http://brcabase.icr.ac.uk. P-value: right-tailed Fischer’s exact test p-value adjusted for false discovery rate - the expected
proportion of false discoveries amongst the rejected hypotheses. GO coverage: percentage of hits/GO genes.
doi:10.1371/journal.pone.0018261.t002
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with our previous data [16,19]. Next, knock-down efficiencies and
specificity of these siRNA were evaluated using RT-qPCR assays
(Fig. 4B–E). Transfection of siRNA targeting ITPKA or PNCK
resulted in a significant decreased expression of their targets
(Fig. 4B and C). For siRNA targeting ITPKA, the mRNA
expression level of the 2 other isoforms (ITPKB and ITPKC) of
ITPK family was tested. ITPKA siRNAs were unable to decrease
mRNA expression of these ITPK isoforms (Fig. 4D). In a similar
manner, PNCK siRNAs failed to decrease mRNA expression of
CaMKIa (Fig. 4E).
PNCK governs phosphorylation state of CaMKIa on
thr177
Considering the consequence of the knock-down of PNCK in
the AhR/CYP1A1 pathway, we hypothesized that PNCK may be
able to phosphorylate CaMKIa on Threonine 177. Such
Figure 4. Hit confirmation and selectivity of siRNA. A, Knock-down of ITPKA, PNCK, CaMKIa and AhR in MCF-7 cells. In this confirmation step, 2
siRNA among 3 of the library were selected for ITPKA and PNCK and effects were compared to those of 2 siRNA targeting CaMKIa and AhR (Positive
controls) and to negative control (siNT1). 72 h after transfection, cells were exposed to 5 nM TCDD for 6 h and EROD activity was measured as
explained in Materials and Methods. Knock-down efficiencies were evaluated by RT-qPCR assays for ITPKA (B) and PNCK (C). Evaluation of off-target
effects of siRNA targeting ITPKA or PNCK through mRNA quantification of ITPKB, ITPKC (D) and CaMKIa (E). mRNA level data are expressed in function
of the values of mRNA levels found in siNT1-transfected cells exposed to TCDD, arbitrarily set to 1; they correspond to the means 6 S.E.M. of three
independent experiments. * p-value,0.05 compared to NT1-transfected cells.
doi:10.1371/journal.pone.0018261.g004
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phosphorylation allows a full activation of CaMKIa as already
demonstrated in rat cells [35]. MCF-7 cells were transfected with
siRNA targeting PNCK or their control (NT1) and 72 h later, cells
were exposed to the calcium ionophore ionomycin, a strong
activator of the Ca2+/CaM/CaMKs cascade [36]. Next, Western-
blots were performed to analyze the phosphorylation state of
CaMKIa on Thr177 (Fig. 5). siRNA targeting PNCK strongly
affected the phosphorylation state of CaMKIa on Thr177, thus
demonstrating that PNCK is able to govern the phosphorylation
state of CaMKIa on Thr177 in human cells.
Discussion
To discover cellular factors implicated in up-regulation of
CYP1A activity in response to TCDD exposure, we performed a
kinome-wide siRNA screen, revealing 22 potential cellular targets
that were not previously linked to this environmental pollutant. In
addition, we provided the identification of a relevant set of kinases,
which interfere with cell proliferation and should be consequently
potential targets for breast cancer therapy.
In accordance with numerous screens using loss of cell functions
[26], the number of hits down-modulating the up-regulation of
CYP1A1 activity was rather limited (approximately 3%), mostly
due to false negatives resulting either from the insufficient activity
of some siRNA, from the high stability of some proteins, or from
the redundancy of some gene functions. This RNAi-based screen
failed to identify CaMKIa as interfering with TCDD-triggered
EROD up-regulation. The reason for this discrepancy is rather
unclear. It is not related to an alteration of cell proliferation (Table
S1) and may reflect an inefficient knock-down of CaMKIa
expression by the siRNA used in the screen.
In the present study we developed a more selective approach to
identify truly kinase involved in EROD regulation. We first
considered a kinase as a potential hit when at least 2 out of 3
siRNA were found into the 150 top z-scores (Table 1), since it is
generally considered that observation of a phenotype caused by
two distinct siRNA sequences indicates that it is unlikely to be the
result of an off-target effect [32]. Second, we focused only on
siRNA influencing the up-regulation of CYP1A1 activity in
response to TCDD exposure, without concomitantly affecting cell
survival and proliferation. We admitted the fact that human
kinases may be necessary for these two processes. As example, the
knock-down of MEK1(MAP2K1), which has been linked to AhR
signaling pathway [37], strongly affected MCF-7 cell density,
evaluated by methylene blue assay (Table S1). In addition, it
should be kept in mind that inactivation of kinases may affect the
TCDD-mediated CYP1A1 activity through an AhR-unrelated
manner, such as, for example, impairment of CYP1A1 protein
synthesis or catalytic activity [17,38,39]. Interestingly, we have
not identified kinase, which negatively regulates the AhR
pathway according to our criteria (at least 2 efficient siRNA out
of 3) among siRNA gene knock-down that increased EROD
activity (Fig. 2B).
Among the 22 kinases identified as potential hits interfering with
the up-regulation of CYP1A1 activity by our RNAi screen, we
confirmed the implication of PNCK and ITPKA through screen-
independent transfection of efficient siRNA.
PNCK/CaMKIb is a member of the calcium/calmodulin-
dependent protein kinase family of protein serine/threonine
kinases [40], known to efficiently activate CaMKIa in rat cells
via Thr177 phosphorylation [35]. Interestingly, we and others
previously demonstrated that Ca2+/CaM/CaMKIa pathway is
likely an important contributing factor to AhR-mediated genomic
response in MCF-7 cells, mouse hepatoma Hepa-1c1c7 cells and
cortical neurons [16,17,18,19], without involvement of CaMK
kinases (CaMKKs), the classical upstream kinases of CaMKs
[16,19]. Intriguingly, the knock-down of only one CaMKI
isoform, PNCK/CaMKIb or CaMKIa allowed a reduction of
TCDD-induced CYP1A1 activity, but not a nearly complete
inhibition as obtained with siRNA targeting AhR (Fig. 4A). These
effects have likely to be compared to knock-down efficiencies
(siRNA targeting PNCK, ,40–50%, CaMKIa, ,75%, AhR,
,85% at mRNA levels (Fig. 4C and data not shown)), and need
further investigation to control the knock-down efficiencies at
protein level. However, the knock-down of PNCK strongly
attenuated the detection of phospho-CaMKIa on Thr177,
suggesting that siRNA-mediated knock-downs are efficient for
impairing functional kinase activities. This is in agreement with
our previous study, in which we demonstrated that knock-down of
CaMKIa abolished CaMKIa activity [19]. Finally, it is tempting
to postulate that both PNCK and CaMKIa are required for Ca2+/
CaMKI/AhR signaling pathway (see hypothetical scheme, Fig.
S4). Here, PNCK was demonstrated to be able to govern the
phosphorylation state of CaMKIa on Thr177 in human cells. This
suggests that PNCK, unlike CaMKKs [16,19], may activate
CaMKIa cells in TCDD-treated cells.
ITPKA regulates inositol phosphate metabolism through
phosphorylation of the second messenger IP3 to IP4. Interestingly,
both calcium/calmodulin and protein phosphorylation mecha-
nisms control its activity [41]. Here, transfection of siRNA
targeting ITPKA decreased EROD activity in TCDD-treated
cells. In addition, inositol polyphosphate multikinase (IPMK) [41],
which is also able to produce IP4, has been identified as a hit.
Therefore, at least two kinases converging to the same pathway
were revealed as interfering with the up-regulation of CYP1A
activity, suggesting a role for IP3/IP4 in the AhR/CYP1A1
pathway. Further investigations are required to elucidate the exact
role of ITPKA, IPMK and of inositol polyphosphates into the
AhR signaling cascade (see hypothetical scheme, Fig. S4).
In summary, our RNAi-based screen of the human kinome
identifies 22 potential cellular kinases interfering with the up-
regulation of CYP1A activity in response to TCDD, especially
PNCK and ITPKA. These kinases were not linked to this
environmental pollutant so far and could be new targets. Finally,
in accordance with literature, our results showed evidence for the
role of calcium, IP3, calmodulin and CaMK in the AhR pathway.
Overall, our RNAi-based screen methodology likely represents
a novel opportunity to characterize signaling pathways activated
by environmental pollutants.
Figure 5. Involvement of PCNK in CaMKIa phosphorylation.
MCF-7 cells were transfected with siRNA targeting PNCK or control
siRNA (NT1) and 72 h later, cells were exposed to the ionophore
ionomycin, a strong activator of the Ca2+/CaM/CaMKs pathway. Next,
Western-blots were performed to analyze the phosphorylation state of
CaMKIa on Thr177. Hsc70 was used as loading control. The data shown
are representative of two independent experiments.
doi:10.1371/journal.pone.0018261.g005
Study of AhR Pathway by Kinome-Wide RNAi Screen
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e18261
Materials and Methods
Chemicals and reagents
Ethoxyresorufin and methylene blue were purchased from
Sigma-Aldrich (St Louis, MO). TCDD was obtained from
Cambridge Isotope Laboratories (Cambridge, MA). Ionomycin
was obtained from Calbiochem (La Jolla, CA). TRIzol reagent was
obtained from Life Technologies (Cergy Pontoise, France).
Monoclonal mouse anti-Hsc70 and rabbit anti-phospho-CaMKIa
(Thr177) Abs were purchased from Santa Cruz Biotechnology (La
Perray en Yvelines, France). Chemicals were commonly used as
stock solution in dimethyl sulfoxide (DMSO). Final concentration
of solvent did not exceed 0.2% (v/v); control cultures received the
same volume of solvent as for treated counterparts.
Cell culture
The estrogen receptor positive cell line MCF-7 was purchased
from European Collection of Cell Cultures (ECACC, Wiltshire,
United Kingdom) and cultured in D-MEMmedium with 4500 mg/
L D-glucose, 110 mg/L sodium pyruvate and non-essential amino
acids, supplemented with 100 U/ml penicillin, 100 U/ml strepto-
mycin and 10% fetal calf serum, as previously described [19].
Ethoxyresorufin O-deethylase (EROD) activity assay
EROD activity, corresponding to the O-deethylation of
ethoxyresorufin, and mainly supported by CYP1A1 enzyme in
living MCF-7 cells, was measured as previously described [19].
Briefly, MCF-7 cells were incubated in phosphate-buffered saline
pH 7.4, containing 5 mM ethoxyresorufin, and kinetic reading
was performed at 37uC with a SpectraMax Gemini SX
spectrofluorometer over a 15 min-period.
Methylene Blue Assay
Cell viability was assessed by a methylene blue colorimetric
assay [42] immediately after EROD activity assay. Briefly, cells
were fixed for at least 30 min in 95% ethanol. Following removal
of ethanol, fixed cells were dried and stained for 30 min with
methylene blue dye (1% in borate buffer). After two washes with
tap water, 100 mL of 0.1 N HCl per well were added. Plates were
next analyzed with a spectrophotometer at 620 nm.
Reverse transfection of siRNA
The protein kinase siRNA library targeting 712 kinases of the
human kinome (MISSION siRNA Human Kinase Panel, 3 siRNA
per target in 3 individual wells, Table S3) has been produced and
aliquoted in 96-well plates by Sigma-Genesys (St. Quentin,
France). 21mer siRNA duplexes with dTdT overhangs have been
produced using Rosetta Inpharmatics design algorithm. The
following siRNA were purchased from Sigma-Genesys: The
positive control siRNA targeting AhR (iAHR), 59-AAGUCGGU-
CUCUAUGCCGCtt-39, control siRNA (iNT1) corresponding to
non-targeting siRNA, 59-UGGUUUACAUGUCGACUAAtt-39,
siRNAs directed against CaMKIa (CaMKIa-1, 59-GCGGUU-
ACCCUCCCUUCUAtt-39, and CaMKIa-2, SASI_Hs01_
00226307), siRNAs directed against PNCK (PNCK-2, 59-CCC-
UUUGAGGACUCGAAGAtt-39, and PNCK-3, 59-GCGUCUA-
CGAGAUCCGCGAtt-39) and siRNAs directed against ITPKA
(ITPKA-2, 59-CCUUGUGUGCUCGACUGCAtt-39, and ITP-
KA-3:59-GGCAGAAGAUCCGGACCAUtt-39 ).
HTS Method
Per well of 96 multiwell plate, 10 pmol of siRNAs were mixed
with 0.3 ml of Dharmafect I reagent (PERBIO SCIENCES
FRANCE, Brebie`res) diluted in 45 ml of transfection medium
(Opti-MEM, Invitrogen, Paisley, UK) for 40 min at room
temperature. Next, 30.000 MCF-7 cells, diluted in complete
culture medium (100 mL), were added per well. 72 h later,
transfected cells were exposed to 5 nM TCDD for 6 h. MCF-7
cells were next used for CYP1A-related EROD activity assay and
methylene blue assay.
CellHTS2 analysis
The dual-channel cell-based high-throughput screens (HTS)
were analyzed using the R package cellHTS2 [25]. This package
was especially developed to pre-process cell-based assays and is
freely available on the Bioconductor project website (http://
bioconductor.org/packages/2.5/bioc/html/cellHTS2.html). Briefly,
data were normalized, and ratio were next calculated (ERODActiv-
ity/Methylene blue, Fig. S3). Then, data were summarized and
finally z-scores were estimated, according to the preprocessing work-
flow for two-channel screens, http://bioconductor.org/packages/
2.5/bioc/vignettes/cellHTS2/inst/doc/twoChannels.pdf).
RNA isolation and analysis
Total RNAs, extracted using the TRIzol method, were
subjected to reverse transcription-real time quantitative polymer-
ase chain reaction (RT-qPCR) analyses as previously described
[19]. Relative quantification of mRNA levels was performed after
normalization of the total amount of cDNA tested to an 18 S RNA
endogenous reference. The sequences of the primers used for RT-
qPCR analysis were the following: 18S sense 59-CGCCGCTA-
GAGGTGAAATTC-39, 18S antisense 59-TTGGCAAATGCTT-
TCGCT-39,
ITPKA sense 59-GCATCGAGGGCATCAAGAAAG-39 ITPKA
antisense 59-GATACCGCCTCAGCACTTCC39, ITPKB sense 59-
TGGCAGGACACGCAGGGAGT-39, ITPKB antisense 59-GGC-
GAGTCGAAGTCGGCCAG-39, ITPKC sense 59-TGCCAGC-
GATCCCGAGGACA-39, ITPKC antisense 59-GGCTGCGCTG-
CTCACACTGA-39, CaMKIa sense 59-CAAAGATTTCATCC-
GGCACT-39, CaMKIa antisense 59-TTGAAGGCTTGCTTCA-
CTT-39, PNCK sense 59-ATGACATCTCAGAATCAGCCAA-
AG-39, PNCK antisense 59-TTCCAGTGTGTCCGAGCAAAG-
39. Gene expression was calculated relative to expression of 18S
endogenous control, and adjusted relative to expression in siRNA
control (iNT1) transfected cells.
Cellular protein extracts and immunoblotting analysis
Cellular protein extracts were prepared using a cell lysis buffer
containing 50 mM HEPES, 150 mM NaCl, 1 mM EGTA, 0.1%
Tween 20, 10% glycerol and 100 mM phenylmethylsulfonyl
fluoride and supplemented with an EDTA-free cocktail protease
inhibitor (Roche Diagnostic, Meylan, France). Protein samples
(50 mg) were next subjected to electrophoresis in a 10% acrylamide
gel and electrophoretically transferred to a nitrocellulose mem-
brane (Bio-Rad, Marne la Coquette, France). After blocking with
Tris-buffered saline containing 4% bovine serum albumin and
0.1% Tween 20 for 1 h at room temperature, membranes were
incubated overnight at 4uC with primary Ab. After incubation
with appropriate horseradish peroxidase-conjugated secondary Ab
for 1 h, immuno-labelled proteins were visualized by autoradiog-
raphy using chemiluminescence.
Statistical analysis
Quantitative data were usually given as means 6 SD of values
from, at least, three independent experiments. Significant
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differences were routinely evaluated with the paired Student’s t-
test. The level of significance was p-value,0.05.
Supporting Information
Figure S1 Methylene blue pictures. Pictures of 3 plates (7-9)
among 30 for the 3 independent experiments. The z-scores,
obtained by using cellHTS2 package for methylene blue data,
were also illustrated. Negative controls: wells A12, B12 and G12,
H12.
(TIF)
Figure S2 Methylene blue data analyses. A, Flow diagram
of the strategy used to identify kinases interfering with cell density
in MCF-7 cells. B, a screen-wide image plot to visualize the
position in plates of hits. Here, the picture corresponds to
individual z-scores calculated from 3 experiments for individual
siRNA. One experiment corresponds to 30 plates. Negative
controls: non-targeting siRNA (NT1) transfected cells and
Dharmafect1-exposed cells (without siRNA). C, hits have been
annotated and next classified in function of kinase families. Here,
we showed only the main represented families. * indicated that at
least 2 siRNA out of 3 have been identified as ‘efficient’. D, Eight
kinases were common to our kinome-wide siRNA screen in MCF-
7 cells and microarrays data obtained from 227 human breast
cancers.
(TIF)
Figure S3 R Script for the cellHTS2 analysis using the
preprocessing work-flow for two-channel screens
(EROD and methylene blue data).
(TIF)
Figure S4 Hypothetical Schema. The diagram shows a
hypothetical schema to resume the AhR signaling pathway leading
to nuclear translocation of AhR and consecutive CYP1A1 up-
regulation and activity (EROD). Ligands of AhR such as TCDD
are known to induce a transient elevation of intracellular
concentration of IP3 and calcium. Calcium and calmodulin
(cam) are required for the full activation and the activity of
CaMKIa, PNCK (CaMKIb) and ITPKA. Two confirmed hits
have been indicated: PNCK and ITPKA. Another hit, IPMK is
also able to convert IP3 to IP4. The identity of the kinase
responsible of ITPKA phosphorylation on Thr311 (symbolized by
CaMK?) is probably an isoform of CaMK type II or PKA [41].
(TIF)
Table S1 List of the individual z-scores for methylene
blue data obtained from MCF-7 cells.
(XLS)
Table S2 List of the mean z-scores for methylene blue
data obtained from MCF-7 cells.
(XLS)
Table S3 The human kinase library used for the RNAi
screen. Positions and sequences of siRNA.
(XLS)
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